New guideline for Helicobacter pylori includes change to primary treatment recommendation

The updated document includes 12 treatment options for this bacterium, which is present in 30 to 40% of the North American population

12:55 PM

Author | Sam Page

bacteria blue yellow
Justine Ross, Jacob Dwyer, Michigan Medicine

The American Journal of Gastroenterology has published a new guideline on the treatment of Helicobacter pylori (H. pylori) Infection.

The corresponding author on the guideline is William D. Chey, M.D., chief of the Division of Gastroenterology and Hepatology at Michigan.

H. pylori is a bacterium that infects over half the people in the world, though most are asymptomatic.

It can cause dyspepsia, peptic ulcer disease and gastric cancer. 

This latest clinical practice guideline notes that its prevalence in North America is decreasing, but it still infects 30-40% of the population.

A previous guideline was published in 2017. It had maintained the recommendation of a proton pump inhibitor-clarithromycin triple therapy as the primary treatment option.

In the new guideline, the number one recommendation for treatment-naïve patients is bismuth quadruple therapy. 

That treatment typically includes a PPI, tetracycline, bismuth and a nitroimidazole for 14 days. 

“We were already recommending that healthcare providers move away from PPI triple therapy in 2017 because of increasing problems with clarithromycin resistance amongst H. pylori strains in the United States,” Chey said. 

“Despite that recommendation, PPI triple therapy still dominates first-line therapy prescriptions for H. pylori patients in the United States. In this newest iteration of the guideline, we are very clear to say that in essentially all circumstances you should not be prescribing PPI triple therapy, and you should be instead using bismuth quadruple therapy or one of the other suggested treatment options.”

The guideline makes 12 total treatment suggestions for patients in a variety of different situations.  

The number two recommendation for treatment-naïve patients—after bismuth quadruple therapy—is rifabutin triple therapy (a PPI, rifabutin and amoxicillin.)

A third option consists of a new, highly potent drug which blocks stomach acid production called vonoprazan combined with the antibiotic amoxicillin.

Besides the move away from PPI triple therapy, another change from the 2017 guideline is the discussion of increasingly available molecular testing for antibiotic susceptibility. 

“Molecular testing really opens the door to the possibility of more liberally utilizing antibiotic sensitivity testing as a mechanism of tailoring therapy to the antibiotics that H. pylori or a person infected with H. pylori is sensitive to,” Chey said. 

The guideline also outlines future research priorities, such as identifying which individuals would most benefit from H. pylori testing to prevent gastric cancer and evaluating newly FDA-approved regimens for persistent infections.

Additional authors: Colin W. Howden, M.D., Steven F. Moss, M.D., Douglas R. Morgan, M.D., M.P.H., Katarina B. Greer, M.D., M.S., Shilpa Grover, M.D., M.P.H., Shailja C. Shah, M.D., M.P.H.

Funding/disclosures: Two authors received a fee for serving as guideline methodologists from the American College of Gastroenterology.

Tech transfer(s)/Conflict(s) of interest: William D. Chey is a consultant for Phathom Pharmaceuticals and RedHill Biopharma

Sign up for Health Lab newsletters today. Get medical tips from top experts and learn about new scientific discoveries every week

Sign up for the Health Lab Podcast. Add us wherever you listen to your favorite shows


More Articles About:

Gastrointestinal Surgery Digestive (GI) Conditions All Research Topics
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

chey-william

William D Chey, MD, MACG, AGAF, FACP, RFF

Professor

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

drawing of scientists and doctors up close to insides of stomach
Health Lab

How a phone call led Michigan Medicine to become a leader in treating severe ulcerative colitis

Michigan Medicine becomes leader in treating severe ulcerative colitis with JAK inhibitors.
Mother sits on a couch with a laptop on her lap while an elementary school age boy sits next to her playing on a tablet device.
Health Lab

New questionnaire aims to improve understanding of demand avoidance in children, teens

Pathological demand avoidance is a pattern of intense distress and avoidance of demands in children. A new questionnaire from University of Michigan researchers creates a structured way to assess these behaviors.
Blue round cells in three pictures showing how they change under stress.
Health Lab

Timing is of the essence for RNA during stress

Key determiners of which RNA can be read to make proteins is time. Previous thinking was that a cell under threat would quickly make these RNAs in the nucleus and immediately push them into the cytoplasm.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
Rachel Upjohn Building groundbreaking ceremony
News Release

How U-M helped bring depression out of the darkness

The history of the founding of the Eisenberg Family Depression Center at the University of Michigan, the nation's first center focused on research, community outreach and stigma reduction in depression and bipolar disorder.